Technical Analysis for CAPR - Capricor Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 0.59 0.85% 0.01
CAPR closed up 0.85 percent on Friday, March 22, 2019, on 46 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Mar 28

*** please verify all earnings dates ***
5 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CAPR trend table...

Date Alert Name Type % Chg
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 New Uptrend Bullish 0.85%
Mar 21 Upper Bollinger Band Walk Strength 0.85%
Mar 21 Wide Bands Range Expansion 0.85%
Mar 21 Above Upper BB Strength 0.85%
Mar 21 Overbought Stochastic Strength 0.85%

Older signals for CAPR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
Biotechnology Life Sciences Cardiovascular Diseases Regulus Therapeutics Two River
Is CAPR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 23 The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Mar 21 Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
Feb 21 Capricor Therapeutics, Inc. (NASDAQ:CAPR): Commentary On Fundamentals
Feb 15 FDA finalizes guidance for expedited review of cell and gene therapy applications
Feb 7 Sangamo selloff weighs on gene therapy developers
Feb 6 Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Jan 24 4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
Jan 24 Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
Jan 22 Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
Jan 18 Does Capricor Therapeutics, Inc.’s (NASDAQ:CAPR) CEO Pay Reflect Performance?
See more CAPR news...
Indicators
Indicator Value
52 Week High 1.67
52 Week Low 0.31
Average Volume 339,359
200-Day Moving Average 0.8916
50-Day Moving Average 0.5083
20-Day Moving Average 0.4947
10-Day Moving Average 0.5293
Average True Range 0.048
ADX 27.47
+DI 27.8449
-DI 8.0537
Chandelier Exit (Long, 3 ATRs ) 0.4638
Chandelier Exit (Short, 3 ATRs ) 0.5566
Upper Bollinger Band 0.5936
Lower Bollinger Band 0.3958
Percent B (%b) 0.98
BandWidth 39.983829
MACD Line 0.0247
MACD Signal Line 0.0091
MACD Histogram 0.0156
Fundamentals Value
Market Cap 13.86 Million
Num Shares 23.5 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 15.44
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.67
Resistance 3 (R3) 0.66 0.63 0.65
Resistance 2 (R2) 0.63 0.61 0.64 0.65
Resistance 1 (R1) 0.61 0.60 0.60 0.62 0.64
Pivot Point 0.58 0.58 0.58 0.59 0.58
Support 1 (S1) 0.56 0.56 0.55 0.57 0.54
Support 2 (S2) 0.53 0.55 0.54 0.53
Support 3 (S3) 0.51 0.53 0.53
Support 4 (S4) 0.52